Immunogen

After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan
After weathering failure, rejection and layoffs, ImmunoGen touts a new 'breakthrough' drug in its comeback plan
Endpoints
Immunogen
FDA
IMGN632
blastic plasmacytoid dendritic cell neoplasm
Flag link:
ImmunoGen cuts deep to eke out cash for mirvetuximab trial
ImmunoGen cuts deep to eke out cash for mirvetuximab trial
Fierce Biotech
Immunogen
R&D
layoffs
Flag link:
A delicate balancing act for Immunogen
A delicate balancing act for Immunogen
EP Vantage
Immunogen
mirvetuximab soravtansin
Jazz Pharmaceuticals
IMGN779
IMGN632
Flag link:
FDA tells ImmunoGen to run a second phase 3, sinking stock
FDA tells ImmunoGen to run a second phase 3, sinking stock
Fierce Biotech
Immunogen
mirevtuximab soravtansine
ovarian cancer
clinical trials
Flag link:
ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint
ImmunoGen Plunges After Phase III Ovarian Cancer Treatment Fails to Hit PFS Endpoint
BioSpace
Immunogen
ovarian cancer
clinical trials
mirvetuximab soravtansine
Flag link:
ImmunoGen Waits to Leap "Forward"
ImmunoGen Waits to Leap "Forward"
Motley Fool
Immunogen
earnings
Flag link:
Synaffix Adds Antibody Drug Conjugate Veteran John Lambert to Scientific Advisory Board
Synaffix Adds Antibody Drug Conjugate Veteran John Lambert to Scientific Advisory Board
CP Wire
Synaffix
Immunogen
antibody-drug conjugate
Flag link:
ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
CP Wire
Immunogen
mirvetuximab soravtansine
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
ImmunoGen Gets Good News From Interim Analysis of Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Immunogen
mirvetuximab soravtansine
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
Alkermes
Immunogen
Sorrento Therapeutics
Flag link:
9 Notable Biotechs Presenting At This Year's ASH Meeting
9 Notable Biotechs Presenting At This Year's ASH Meeting
Yahoo
ASH
Bluebird Bio
LentiGlobin
Ziopharm Oncology
Bellicum
BPX-501
Spark Therapeutics
SPK-8011
Biomarin
BMN 270
Juno Therapeutics
CAR-T
Novartis
Geron
imetelstat
Immunogen
IMGN632
IMGN779
Flag link:
Jazz, ImmunoGen partner on hematology, oncology drug development
Jazz, ImmunoGen partner on hematology, oncology drug development
BioPharma Dive
Jazz Pharmaceuticals
Immunogen
oncology
hematology
drug development
Flag link:
Why ImmunoGen, Inc. Jumped Higher Today
Why ImmunoGen, Inc. Jumped Higher Today
Motley Fool
Immunogen
anetumab ravtansine
Bayer
mesothelioma
Flag link:
5 Best Biotech Stocks of 2017 So Far
5 Best Biotech Stocks of 2017 So Far
Motley Fool
biotech
Alnylam
Puma Biotechnology
Immunogen
Sangamo BioSciences
Calitera
Flag link:
Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio
Sanofi beefs up cancer drug pipeline, paying cash hungry ImmunoGen $30M for full rights to oncology portfolio
Endpoints
Sanofi
Immunogen
oncology
M&A
isatuximab
Multiple Myeloma
Flag link:
ImmunoGen’s new CEO retrenches, axing 65 staffers and looking to thin pipeline
ImmunoGen’s new CEO retrenches, axing 65 staffers and looking to thin pipeline
Endpoints
Immunogen
layoffs
Flag link:
Here are 13 MA cancer biotechs hoping to make waves next month
Here are 13 MA cancer biotechs hoping to make waves next month
Bizjournals.com
Boston
biotech
ASCO 2016
Ariad Pharmaceuticals
Immunogen
Ziopharm
Vertex Pharmaceuticals
Tokai
Infinity Pharmaceuticals
Momenta
Merrimack
Tesaro
Syndax
Kyropharm
Foundation Medicine
Cerulean Pharma
Flag link:
8 Biotech Stocks Under $10 Making Big Moves Higher
8 Biotech Stocks Under $10 Making Big Moves Higher
TheStreet.com
Dicerna
Novadaq Technologies
Idera Pharmaceuticals
Versartis
ProNai
Immunogen
Medgenic
Inotek
Flag link:
Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda
Here's why ImmunoGen's CEO is psyched for combo tests with Keytruda
Bizjournals.com
Merck
Immunogen
Keytruda
maytansine
Dan Junius
Flag link:
ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients
ImmunoGen Refines Drug Targeting for Ovarian Cancer Patients
TheStreet.com
Immunogen
ovarian cancer
mirvetuximab soravtansin
clinical trials
Flag link:

Pages